Tjoa B, Boynton A, Kenny G, Ragde H, Misrock S L, Murphy G
Pacific Northwest Cancer Foundation, Northwest Hospital, Seattle, Washington 98125, USA.
Prostate. 1996 Jan;28(1):65-9. doi: 10.1002/(SICI)1097-0045(199601)28:1<65::AID-PROS9>3.0.CO;2-N.
Dendritic cells (DCs) are "professional" antigen-presenting cells capable of stimulating T-cell proliferation and cytotoxicity when loaded with and presenting specific antigens, including tumor antigens. We demonstrated the stimulation of an autologous cytotoxic T-cell response elicited by DC loaded with autologous tumor cell lysate derived from primary prostate tumor. A candidate tumor antigen is prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer patients. We identified a HLA-A2 motif in PSMA, isolated patient DC, loaded peptide into DC, and stimulated autologous T cells to proliferate. The ability to use DC for presentation of either tumor or peptide antigen in an HLA-restricted fashion in order to stimulate T-cell proliferation and cytotoxicity demonstrates the potential of this technology for development of a prostate cancer vaccine.
树突状细胞（DCs）是“专职”抗原呈递细胞，当负载并呈递特定抗原（包括肿瘤抗原）时，能够刺激T细胞增殖和细胞毒性。我们证明了负载源自原发性前列腺肿瘤的自体肿瘤细胞裂解物的DC可引发自体细胞毒性T细胞反应。一种候选肿瘤抗原是前列腺特异性膜抗原（PSMA），其在前列腺癌患者中过度表达。我们在PSMA中鉴定出一个HLA - A2基序，分离出患者的DC，将肽加载到DC中，并刺激自体T细胞增殖。以HLA限制方式使用DC呈递肿瘤或肽抗原以刺激T细胞增殖和细胞毒性的能力证明了该技术在开发前列腺癌疫苗方面的潜力。
